EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Prophylaxis of migraine, transformed migraine, and cluster headache with topiramate



Prophylaxis of migraine, transformed migraine, and cluster headache with topiramate



Headache 42(8): 796-803, September



Objective: To assess the efficacy and tolerability of topiramate for prophylaxis of migraine and cluster headache via a retrospective chart analysis. Background: Topiramate has multiple mechanisms of action that could potentially contribute to migraine prophylaxis. We conducted a retrospective chart review to assess the efficacy of topiramate as add-on therapy in patients with transformed migraine or cluster headache, and as first-line therapy in patients with episodic migraine. Methods: Patients diagnosed with transformed migraine, episodic migraine, or cluster headache, who received topiramate either as add-on therapy or monotherapy were selected via retrospective chart review. Patients had begun topiramate therapy at 25 mg/day for the first week and increased their dosage by 25 mg/week to a maximum of 200 mg/day. Topiramate was used as add-on therapy for patients with transformed migraine and cluster headache, and as a first-line monotherapy in patients with episodic migraine who had no previous prophylactic therapy. The outcome parameters examined included a mean 28-day migraine frequency, migraine severity, number of headache days/month, number of abortive medication tablets/month, patient global evaluation, and the MIDAS scale. Results: One hundred seventy-eight patients (transformed migraine: n=96; episodic migraine: n=70; and cluster headache: n=12) were included in the retrospective analysis. The mean dose of topiramate for all patients was 87.5 mg/day. For patients with transformed migraine, mean migraine frequency decreased from 6.3/28 days to 3.7 (P=0.005). Mean severity decreased from 7.1 to 3.8 on a 10-point scale, with 10 representing the most severe pain (P=0.003). The mean number of headache days/month decreased from 22.1 to 9.6 (P=0.001), and the mean number of abortive medication tablets decreased from 28.7/month to 10.6 (P=0.001). Patient global evaluation indicated substantial or moderate improvement in 53% of patients with transformed migraine who used topiramate as add-on therapy. Mean MIDAS scale values decreased from 90.2 to 24.9 (P<0.0001). The 70 episodic migraine patients who were administered topiramate as first-line therapy exhibited a decrease in mean migraine frequency (5.8/28 days to 1.9, P=0.001), while mean migraine severity decreased from 8.1 to 2.0 (P=0.003). Sixty-one percent of patients reported marked improvement. Nine of the 12 cluster headache patients exhibited substantial or moderate improvement in symptoms, whereas three had no improvement. The most common adverse effects were paresthesias (12%), cognitive effects (11%), and dizziness (6%). Eight patients discontinued topiramate due to adverse effects; cognitive effects were the most common reason. No patient discontinued topiramate treatment due to lack of efficacy. Twelve percent of patients lost more than 5 lbs during treatment (a range of 5-120 lbs). Conclusion: For both patients with transformed migraine (add-on therapy) and patients with episodic migraine (first-line monotherapy), topiramate yielded significant reductions in migraine frequency, migraine severity, number of headache days/month, and use of abortive medications. Topiramate also appears to be well tolerated and useful in the adjunctive treatment of cluster headache. Prospective double-blind, placebo-controlled trials will be required to confirm our results.

(PDF emailed within 0-6 h: $19.90)

Accession: 011212089

Download citation: RISBibTeXText

PMID: 12390644

DOI: 10.1046/j.1526-4610.2002.02183.x



Related references

Low-dose topiramate in migraine and transformed migraine prophylaxis. Cephalalgia 23(7): 721, September, 2003

Therapy of migraine attacks and migraine prophylaxis: Recommendations by the German Society for Migraine and Headache (DMKG). Aktuelle Neurologie 27(6): 273-282, 2000

Treatment of migraine attacks and migraine prophylaxis: recommendations of the German Migraine and Headache Society. Medizinische Monatsschrift für Pharmazeuten 21(2): 30-39, 1998

Headache in migraine patients receiving topiramate: a mere migraine attack or a harbinger of ciliochoroidal effusion syndrome?. Acta Neurologica Belgica 112(3): 305-306, 2013

Rizatriptan for treatment of acute migraine in patients taking topiramate for migraine prophylaxis. Headache 52(1): 57-67, 2012

Antiepileptic drugs in the prophylaxis of migraine, chronic headache forms and cluster headache: a review of their efficacy and tolerability. Neurological Sciences 28 Suppl 2: S188-S197, 2007

Different Effects of Budipine for the Prophylactic Treatment of Cluster Headache, Cluster Migraine, and Migraine. Cephalalgia 9(10_suppl): 408-409, 1989

Pain thresholds in daily transformed migraine versus episodic migraine headache patients. Headache 45(8): 992-998, 2005

Chronic daily headache Transformed migraine is not different from episodic migraine when the IHS criteria are applied both globally and individually. Neurology 54(7 Supp 3): A130, April 11, 2000

Valproate semisodium ER for migraine and cluster headache prophylaxis. Expert Opinion on Drug Metabolism & Toxicology 6(4): 495-504, 2010

Migraine, tension-type headache, and transformed migraine. Current Pain and Headache Reports 11(6): 449-453, 2008

Re: "Naratriptan in the prophylaxis of transformed migraine" (Sheftell FD Rapoport AM, Coddon DR. Headache.1999,39:506-510). Headache 40(3): 252-252, 2000

Topiramate-induced depression in cases using topiramate for migraine prophylaxis. Cephalalgia 30(6): 747-749, 2011

Comparison of cortical excitability in chronic migraine (transformed migraine) and migraine without aura. A transcranial magnetic stimulation study. Journal of Neurology 249(9): 1268-1271, 2002

Methionine-enkephalin in migraine and tension headache. Differences between classic migraine, common migraine and tension headache, and changes during attacks. Headache 30(3): 160-164, 1990